 Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharmas Global Infrastructure to Provide Broad Access to Deuruxolitinib for Patients with Alopecia Areata Strengthens Sun Pharmas Global Dermatology Franchise by Adding a Late-Stage Product in an Area with Significant Unmet Need Sun Pharma to... The post Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopec... 